Ann: Corporate Presentation, page-44

Bpharma, I think what Burt was at risk of is sepsis and to treat that infection with Recce would have required intravenous application. As Andrewk mentioned, what we have with the Burns trial is topical application and building on that approval emergency access was given for the sinusitis case (successfully treated). Treating the sinusitis case was nasal spray application, which is not too far removed from topical and thus I think would have an easier passage of emergency approval; as opposed to intravenous application (for sepsis) which is a far bigger leap/risk profile. In my view Intravenous application needs to go through the full trial process before we start giving emergency approval for treating any condition, the risk of adverse effect is not worth taking before full trial as any bad outcome could potentially set us back years!